Immunotherapy for cardiovascular disease

Esther Lutgens, Dorothee Atzler, Yvonne Döring, Johan Duchene, Sabine Steffens, Christian Weber

Abstract

The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1b antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD.

Original languageEnglish (US)
Pages (from-to)3937-3946
Number of pages10
JournalEuropean heart journal
Volume40
Issue number48
DOIs
StatePublished - Dec 21 2019

Keywords

  • Cardiovascular disease
  • Coronary artery disease
  • Inflammation
  • Novel targets • cytokines
  • Novel therapies

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Immunotherapy for cardiovascular disease'. Together they form a unique fingerprint.

Cite this